

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Prolonged-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Advicenne (Sibnaya) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Genetic Alliance • Kidney Care UK • Kidney Research UK • National Kidney Federation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • Association of Renal Technologists • British Association of Paediatric Nephrology • British Association of Urological Nurses • British Geriatrics Society • British Renal Society • British Society for Genetic Medicine • British Society for Human Genetics • British Society of Paediatric Endocrinology & Diabetes • National Metabolic Biochemistry Network • Neonatal and Paediatric Pharmacists Group • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Alturix (potassium bicarbonate) • Aspire Pharma (sodium bicarbonate) • Baxter Healthcare (citric acid, sodium citrate, sodium bicarbonate, potassium citrate) • Casen Recordati (citric acid) • Ennogen (sodium bicarbonate) • Ethypharm (sodium citrate, sodium bicarbonate) • Ferring Pharmaceuticals (citric acid) • Forum/Barentz (sodium bicarbonate, potassium bicarbonate) • Galen (sodium bicarbonate)

Stakeholder list for the technology appraisal of prolonged-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis ID3787

Issue date: May 2021

Appendix A

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Society for DGH Nephrologists • Society for Endocrinology • UK Clinical Pharmacy Association • UK Genetic Testing Network • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Barnsley CCG • NHS England • NHS West Lancashire CCG • Welsh Government 	<ul style="list-style-type: none"> • GlaxoSmithKline (citric acid, sodium bicarbonate) • Mylan (sodium bicarbonate) • Norgine (sodium bicarbonate) • ParaPharm Development (citric acid, sodium bicarbonate) • Pinewood Healthcare (citric acid, sodium citrate, sodium bicarbonate) • Recipharm (sodium citrate) • Sanofi (sodium citrate, potassium citrate) • Stirling Anglian Pharmaceuticals (sodium bicarbonate) • Teva (sodium bicarbonate) • Thame Laboratories (sodium bicarbonate) • Thornton & Ross (citric acid, sodium bicarbonate, potassium citrate) • Tillotts Pharma (sodium bicarbonate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney and Transplant Group • Cochrane Metabolic & Endocrine Disorders Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.